Bioasis Technologies Inc. (BIOAF)

Overview

Bioasis Technologies Inc. is a pioneering biopharmaceutical company in its development phase, primarily focused on researching and developing innovative solutions for diagnosing and treating neurological diseases and disorders. The company was founded in 2006 and is situated in New Haven, Connecticut. Bioasis Technologies Inc. is at the forefront of crossing the formidable barrier of delivering therapeutic agents across the blood-brain barrier (BBB), a crucial step in treating central nervous system disorders including, but not limited to, brain cancers, metabolic diseases, and neurodegenerative disorders. Its commitment to advancing CNS disorder treatments outlines its pivotal role in the biopharmaceutical field.

Products and Services

Bioasis Technologies Inc. is dedicated to the development of a variety of therapeutic solutions, each aimed at addressing critical aspects of neurological diseases and disorders:

• xB3 Platform Technology: This innovative platform is designed to facilitate the transport of therapeutic agents across the blood-brain barrier (BBB), opening new pathways for treating central nervous system disorders. It represents a significant breakthrough in medical science, with the potential to deliver treatments directly to the brain, thereby improving outcomes for patients suffering from CNS disorders.
• In-House Development Programs:
  • Brain Metastases (xB3-001): Tailored treatment options are being developed to target and manage brain metastases, potentially providing new hope for patients faced with this challenging diagnosis.
  • Glioblastoma (xB3-002): Focusing on one of the most aggressive and difficult to treat brain tumors, Bioasis' xB3-002 program aims at creating more effective therapies for glioblastoma patients.
  • Neurodegenerative Diseases (xB3-007): This program is directed towards discovering symptomatic and disease-modifying treatments for neurodegenerative diseases, promising a brighter future for those affected by these debilitating conditions.
• Collaborative Research Efforts: Bioasis Technologies Inc. has entered into several strategic collaborations to enhance the scope and efficacy of its treatments:
  • Aposense Limited: This collaboration is focused on delivering siRNA therapeutics for CNS disorders, combining expertise to conquer complex challenges.
  • Oxyrane UK Ltd.: A partnership aimed at merging Bioasis' xB3 technology with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery into the brain for more effective treatment options.
  • Janssen Biotech, Inc.: A joint effort to research, develop, and commercialize novel products based on the xB3 platform, highlighting the widespread interest and potential in Bioasis' technologies.
  • Neuramedy Co Ltd.: Collaboration on an xB3TM version of the antibody, Tomaralimab, to research, develop, and commercialize treatments, showcasing Bioasis' commitment to advancing medical science through partnerships.